Mylan’s protracted $12bn merger with Pfizer’s Upjohn off-patent and mature brands unit has today completed, bringing the curtain down on Mylan after nearly six decades of operations and launching a new global player, Viatris.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?